PSMA PET for Prostate Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Prostate Cancer+2 More
PSMA PET - DiagnosticTest
Eligibility
18+
Male
What conditions do you have?
Select

Study Summary

This trial will follow patients who had high-risk results on a previous study to see if they benefit from additional testing and treatment recommendations.

Eligible Conditions
  • Prostate Cancer
  • Prostate Cancer - Recurrent

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Up to 5 years

Up to 5 years
Concordance (AUC) Between High Tumor GC Risk Score and Positive PSMA-PET Imaging Findings
Rate of Positive PSMA-PET Findings

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Radioactive Diagnostic Imaging
1 of 1

Experimental Treatment

60 Total Participants · 1 Treatment Group

Primary Treatment: PSMA PET · No Placebo Group · Phase 2 & 3

Radioactive Diagnostic ImagingExperimental Group · 2 Interventions: F-DCFPyL Injection, PSMA PET · Intervention Types: Drug, DiagnosticTest

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 5 years

Who is running the clinical trial?

Progenics Pharmaceuticals, Inc.Industry Sponsor
30 Previous Clinical Trials
4,795 Total Patients Enrolled
16 Trials studying Prostate Cancer
2,252 Patients Enrolled for Prostate Cancer
H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
490 Previous Clinical Trials
123,334 Total Patients Enrolled
25 Trials studying Prostate Cancer
3,598 Patients Enrolled for Prostate Cancer
Kosj Yamoah, M.D., Ph.D.Principal InvestigatorH. Lee Moffitt Cancer Center and Research Institute
2 Previous Clinical Trials
284 Total Patients Enrolled
2 Trials studying Prostate Cancer
284 Patients Enrolled for Prostate Cancer

Eligibility Criteria

Age 18+ · Male Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have had a radical prostatectomy (RP) or radiation therapy (RT) with ≥2 years follow up.
The testing was successfully completed on biopsy and/or surgical specimen.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 25th, 2021

Last Reviewed: November 28th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.